Loading...

Ion Beam Applications SA

IBAB.BREURONEXT
HealthcareMedical - Devices
$11.58
$0.02(0.17%)

Ion Beam Applications SA (IBAB.BR) Stock Overview

Explore Ion Beam Applications SA’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for IBAB.BRStats details for IBAB.BR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for IBAB.BRAnalyst Recommendations details for IBAB.BR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

CEO

Mr. Olivier Legrain

Employees

2,118

Headquarters

3, Chemin du Cyclotron, Louvain-la-Neuve

Founded

2000

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.